Skip navigation
Agenda

Driving Value Creation and Risk-Balanced R&D Productivity through Operational Excellence and Asset Development Strategy

August 8-9, 2017
  • Cambridge, MA

Agenda

Want more agenda details? Download the brochure.

DAY ONE TUESDAY, AUGUST 8, 2017

7:30

Summit Registration and Continental Breakfast

8:30

Chairman’s Welcome and Opening Remarks

Peter Ray
Executive Director, Corporate Strategy
Celgene

8:45

IN-CONFERENCE WORKSHOP
Analyze Customer Value Curves to Drive Value Creation

Workshop Objective:

Learn to listen differently to gain a new, holistic and measurable understanding of how your customers experience and live their everyday lives in the context of pharmaceuticals and medical devices. Design and conduct clinical trials and enroll patients while including differentiating features that address a broad array of unmet customer issues to provide more insightful evidence. Apply straightforward methods to translate what your customers most value into strategic and operational portfolios. Optimize your portfolio using simple visual tools that define the range of your investments across the range of your customer’s value.

Workshop Outline:

I. What Has Been Missing in Understanding Customer Needs?

II. How to Distinguish Between What the Customer Values and What They Will Pay For — and Even Better, What They Will Pay a Lot More For

III. How to Objectively Evaluate and Make Trade-offs in My Portfolio of Investments Based on Customer Value

Workshop Leader:

Wayne Mackey
Principal
Product Development Consulting, Inc.

12:00

Networking Luncheon

1:15

INDUSTRY KEYNOTE ADDRESS
Market Trends Impacting Portfolio Decision-Making

Peter Ray
Executive Director, Corporate Strategy
Celgene

The Summit Agenda is designed to address four major types of decisions impacting R&D productivity and value creation —
from the highest level of deciding “where to play” and how to optimally structure the R&D organization, to the intermediate levels of strategic portfolio prioritization and operational alignment, and to the most granular level of optimizing the clinical development strategy for specific molecules. Additionally, there will be a session focused on different tools available to support decision-making across the continuum.

2:00

R&D PORTFOLIO STRATEGY
Defining the Capabilities Required to Improve R&D Productivity

Kenneth I. Kaitin, PhD
Professor of Medicine and Director, Tufts Center for the Study of Drug Development
Tufts University School of Medicine

Rushi Potdar, MD, MBA
Director, R&D Strategy & Business Operations
Johnson & Johnson Medical Devices

Soomin Park
Managing Director, Lilly Chorus
Eli Lilly and Company

3:30

Networking and Refreshment Break

4:00

STRATEGIC PORTFOLIO MANAGEMENT
Optimize and Prioritize Current Assets and Projects

MODERATOR:

Rob Liebman, MBA
Managing Director
Converge Advisory Group

PANELISTS:

Ivan Kugener, MD
Vice President, Global Head of Portfolio Management, Valuation and Analytics
EMD Serono

Soomin Park
Managing Director, Lilly Chorus
Eli Lilly and Company

Chris Franco, PhD
Director, Global Portfolio Strategy
Takeda

Daniel Rosan
Director, R&D Resource and Performance Management
Biogen

5:30

Close of Day One

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO WEDNESDAY, AUGUST 9, 2017

7:45

Continental Breakfast

8:15

Chairman’s Review of Day One

Peter Ray
Executive Director, Corporate Strategy
Celgene

8:30

OPERATIONAL PORTFOLIO MANAGEMENT
Strategies to Execute Portfolio Strategy

Michael Ferrante
Director, R&D Business Operations
Bristol-Myers Squibb

Grace Nakayama, PhD, PMP
Senior Manager, Program Management
Intercept Pharmaceuticals

Emily Gros
Head, Business Information Reporting and Analytics
Astellas

10:15

Networking and Refreshment Break

10:45

Examine the Latest Innovations in Portfolio Optimization Tools

Wendi Lau
Executive Director Business Operations & Portfolio Analytics, Development
Astellas Pharma Global Development

11:30

Connecting AI and Human Experience to Increase Pipeline Productivity

Subha B. Basu, PhD, MBA
Managing Director
Converge Advisory Group

12:15

Networking Luncheon

1:15

ASSET STRATEGY
Determine the Right Projects with Available Assets to Achieve Portfolio Strategy

Michael Ferrante
Director, R&D Business Operations
Bristol-Myers Squibb

Ivan Kugener, MD
Vice President, Global Head of Portfolio Management, Valuation and Analytics
EMD Serono

Leslie Lippard
Associate Director, Pipeline and Portfolio Planning
Genentech

2:45

Chairman’s Review of Summit Takeaways

3:00

Close of Summit

Agenda

Want more agenda details? Download the brochure.
Want more agenda details? Download the brochure.

DAY ONE TUESDAY, AUGUST 8, 2017

7:30

Summit Registration and Continental Breakfast

8:30

Chairman’s Welcome and Opening Remarks

Peter Ray
Executive Director, Corporate Strategy
Celgene

8:45

IN-CONFERENCE WORKSHOP
Analyze Customer Value Curves to Drive Value Creation

Workshop Objective:

Learn to listen differently to gain a new, holistic and measurable understanding of how your customers experience and live their everyday lives in the context of pharmaceuticals and medical devices. Design and conduct clinical trials and enroll patients while including differentiating features that address a broad array of unmet customer issues to provide more insightful evidence. Apply straightforward methods to translate what your customers most value into strategic and operational portfolios. Optimize your portfolio using simple visual tools that define the range of your investments across the range of your customer’s value.

Workshop Outline:

I. What Has Been Missing in Understanding Customer Needs?

II. How to Distinguish Between What the Customer Values and What They Will Pay For — and Even Better, What They Will Pay a Lot More For

III. How to Objectively Evaluate and Make Trade-offs in My Portfolio of Investments Based on Customer Value

Workshop Leader:

Wayne Mackey
Principal
Product Development Consulting, Inc.

12:00

Networking Luncheon

1:15

INDUSTRY KEYNOTE ADDRESS
Market Trends Impacting Portfolio Decision-Making

Peter Ray
Executive Director, Corporate Strategy
Celgene

The Summit Agenda is designed to address four major types of decisions impacting R&D productivity and value creation —
from the highest level of deciding “where to play” and how to optimally structure the R&D organization, to the intermediate levels of strategic portfolio prioritization and operational alignment, and to the most granular level of optimizing the clinical development strategy for specific molecules. Additionally, there will be a session focused on different tools available to support decision-making across the continuum.

2:00

R&D PORTFOLIO STRATEGY
Defining the Capabilities Required to Improve R&D Productivity

Kenneth I. Kaitin, PhD
Professor of Medicine and Director, Tufts Center for the Study of Drug Development
Tufts University School of Medicine

Rushi Potdar, MD, MBA
Director, R&D Strategy & Business Operations
Johnson & Johnson Medical Devices

Soomin Park
Managing Director, Lilly Chorus
Eli Lilly and Company

3:30

Networking and Refreshment Break

4:00

STRATEGIC PORTFOLIO MANAGEMENT
Optimize and Prioritize Current Assets and Projects

MODERATOR:

Rob Liebman, MBA
Managing Director
Converge Advisory Group

PANELISTS:

Ivan Kugener, MD
Vice President, Global Head of Portfolio Management, Valuation and Analytics
EMD Serono

Soomin Park
Managing Director, Lilly Chorus
Eli Lilly and Company

Chris Franco, PhD
Director, Global Portfolio Strategy
Takeda

Daniel Rosan
Director, R&D Resource and Performance Management
Biogen

5:30

Close of Day One

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO WEDNESDAY, AUGUST 9, 2017

7:45

Continental Breakfast

8:15

Chairman’s Review of Day One

Peter Ray
Executive Director, Corporate Strategy
Celgene

8:30

OPERATIONAL PORTFOLIO MANAGEMENT
Strategies to Execute Portfolio Strategy

Michael Ferrante
Director, R&D Business Operations
Bristol-Myers Squibb

Grace Nakayama, PhD, PMP
Senior Manager, Program Management
Intercept Pharmaceuticals

Emily Gros
Head, Business Information Reporting and Analytics
Astellas

10:15

Networking and Refreshment Break

10:45

Examine the Latest Innovations in Portfolio Optimization Tools

Wendi Lau
Executive Director Business Operations & Portfolio Analytics, Development
Astellas Pharma Global Development

11:30

Connecting AI and Human Experience to Increase Pipeline Productivity

Subha B. Basu, PhD, MBA
Managing Director
Converge Advisory Group

12:15

Networking Luncheon

1:15

ASSET STRATEGY
Determine the Right Projects with Available Assets to Achieve Portfolio Strategy

Michael Ferrante
Director, R&D Business Operations
Bristol-Myers Squibb

Ivan Kugener, MD
Vice President, Global Head of Portfolio Management, Valuation and Analytics
EMD Serono

Leslie Lippard
Associate Director, Pipeline and Portfolio Planning
Genentech

2:45

Chairman’s Review of Summit Takeaways

3:00

Close of Summit